Jennifer Reinhardt

Jennifer Reinhardt is a dedicated patient advocate whose work has helped shape rare disease policy in Colorado and beyond. As a mother to a daughter with a rare disease, she played a key role in the first Colorado Prescription Drug Affordability Board (PDAB) drug review, working alongside other families to successfully oppose an Upper Payment Limit (UPL) on Trikafta and protect access to life-saving treatment. She also partnered with the Goldwater Institute as the lead patient advocate to help pass Right to Try 2.0 in Colorado, expanding access to innovative therapies for critically ill patients. Jennifer continues to advocate for a rare disease carve-out within the PDAB framework in Colorado—an effort that has already led to meaningful progress, including requirements for the board to consult the Rare Disease Advisory Council (RDAC) when reviewing rare disease drugs. Her advocacy is deeply personal: her daughter Maya, born with cystic fibrosis and a congenital heart defect, faced life-threatening complications when antibiotic-resistant pseudomonas left her with no treatment options. Through Right to Try, Jennifer helped secure access to a custom bacteriophage therapy from Tbilisi, which ultimately saved Maya’s life. Today, because of that intervention and subsequent treatment with Trikafta, Maya has full lung function at age 24—an outcome that remains rare in the cystic fibrosis community for people in their 20s. As a single mother and real estate professional, Jennifer continues to fight for policies that protect access to care, driven by the belief that no family should have to endure preventable suffering to be understood.